drugset
drugset / Trial / NCT02509117

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

NCT02509117 ↗

Phase 1 Completed 55 enrolled Pfizer
RandomizedTriple-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.

Timeline

Start
2015-07
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-06751979 Unknown 3 mg Oral
Subject PF-06751979 Unknown 5 mg Oral
Subject PF-06751979 Unknown 12 mg Oral
Subject PF-06751979 Unknown 15 mg Oral
Subject PF-06751979 Unknown 40 mg Oral
Subject PF-06751979 Unknown 50 mg Oral
Subject PF-06751979 Unknown 160 mg Oral

Indications

No indication recorded.